|
| |
Image Results
Loading...
Loading...
Immunogen Patents Pages on BioPortfolio:
|
BioPortfolio - Aphton Corporation - Profile
Aphton Corporation Patents: • 6861510- Immunogenic compositions against gastrin peptides. • 4814170- Method for immunization against and treatment of ...
http://www.bioportfolio.com/biocorporate/18569-Aphton+Corpor...
|
BioInvent Issued US Patent for n-CoDeR Antibody Library
11 Jan 2006 ... BioInvent has already obtained corresponding patents in Europe, ... Antisoma, Celltech, GlaxoSmithKline, Igeneon, ImmunoGen, OrbusNeich, ...
http://www.bioportfolio.com/biotech_news/BioInvent_5.htm...
|
BioPortfolio - CXCR7 - chemokine (C-X-C motif) receptor 7
Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic ... Patents logo. US Patent No. Title. 7598028, Compositions and methods for ...
http://www.bioportfolio.com/gene/57007-CXCR7.html...
|
BioPortfolio - Aphton Corporation
Aphton Corporation Patents: US Patent No. Title. 6861510, Immunogenic compositions against gastrin peptides. 4814170, Method for immunization against
and ...
http://www.bioportfolio.com/biocorporate/395-Aphton_Corporat...
|
BioPortfolio - United Biomedical Inc - Profile
6811782- Peptide composition as immunogen for the treatment of allergy ... information resources: publications, clinical trials, patents and global news.
...
http://www.bioportfolio.com/biocorporate/10466-United%2BBiom...
|
BioPortfolio - Prodrugs
13 Oct 2009 ... Prodrugs Patents: USPTO Logo. US Patent No. Title ... ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. ...
http://www.bioportfolio.com/indepth/Prodrugs.html...
|
BioPortfolio - Intestinal Secretions
Intestinal Secretions Patents: USPTO Logo. US Patent No. Title. 7015016, Use of inactivated immunosuppressive or angiogenic immunogenic proteins for ...
http://www.bioportfolio.com/indepth/Intestinal_Secretions.ht...
| Results from other life science and pharmaceutical sites:
Technology evaluation: C242-DM1, ImmunoGen Inc.
EP-00425235, held by ImmunoGen, covers conjugated forms of ansamitocin ( maytansine) derivatives. Takeda holds several patents for the production of ...
http://www.ncbi.nlm.nih.gov/pubmed/11338934...
|
Our Latest Innovations: ImmunoGen, Inc.
1 May 2009 ... ImmunoGen is committed to maintaining our leadership position in our field ... We have submitted patents on these new linkers and have also ...
http://www.immunogen.com/wt/page/orange_latest_tech...
|
News: Bayer Pays $4M Upfront to Use ImmunoGen's Technology for a ...
21 Oct 2008 ... ImmunoGen will receive an upfront payment of $4 million. ... New Recommendations for Gene Patents - Thank Goodness! ...
http://www.genengnews.com/news/bnitem.aspx?name=43919045...
|
Adjuvants and delivery issues related to immunization: a survey of ...
Such a rational approach to immunogen design results in what has been termed ... In this editorial, I review the recent patent literature as it pertains to ...
http://www.ncbi.nlm.nih.gov/pubmed/9894692...
|
News: ImmunoGen Earns Milestone with Biogen Idec's IND Filing for ...
1 Feb 2008 ... ImmunoGen reports that Biogen Idec submitted an IND application for a cancer drug ... New Recommendations for Gene Patents - Thank Goodness! ...
http://www.genengnews.com/news/bnitem.aspx?name=29733936...
|
FCR 14
U.S. Patent Application Serial Number: (to be assigned), filed September 1, 2004 , titled “TAT AS AN IMMUNOGEN” Inventor: Dr. Avindra Nath. The present ...
http://www.uky.edu/Trustees/agendas/full/dec04/fcr14.pdf...
|
News: ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 ...
29 Oct 2009 ... ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted ... New Recommendations for Gene Patents - Thank Goodness! ...
http://www.genengnews.com/news/bnitem.aspx?name=66846694...
|
A Randomized Controlled Phase IIb Trial of Antigen-Antibody ...
A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex .... ratio (described in US patent 6221664 B1 and European patent 913157), ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24...
|
Office of Patents and Licensing Biomarkers and Diagnostics
predominant immunogen in ulcerative colitis patients. UC is difficult to diagnose because .... contact Judith Ladd at the Office of Patents and Licensing
. ...
http://www.umdnj.edu/resrhweb/patents/for_licensing/diagnost...
|
Evaluation of the effects of a new drug candidate (GEMSP) in a ...
19 May 2008 ... GEMSP was synthesized according to patent numbers 6114388 (USA) and ..... is a non-immunogenic peptide (see patent numbers of GEMSP: 6114388 ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24...
|
|
